source
- AstraZeneca hints restructuring may trim R&D budget and move trials to emerging marketsAstraZeneca's chief executive Pascal Soriot told journalists that the company's new restructuring program could lead to cost reductions in research and development and may see some clinical trials…
- AstraZeneca launches $1.5 billion cost-saving plan to fund growth, says no layoffs expectedAstraZeneca announced a three-year cost‑saving initiative worth $1.5 billion during its third‑quarter earnings call. The program, called Reshaping for Sustainable Growth, aims to redeploy resource…